Thursday, May 23, 2013
An Israeli academic-industry partnership has discovered small
molecules that interfere wi th signaling by insulin-like
growth factor-1 receptor, a cancer-associated receptor
tyrosine kinase. The new compounds, licensed to NovoTyr Therapeutics Ltd., could
be superior to conventional approaches to hitting this target because they
cause destruction of two key downstream effectors, insulin
1 and insulin
receptor substrate 2.1
Osherovich, L. SciBX 6(20); doi:10.1038/scibx.2013.478
Published online May 23, 2013
1. Reuveni, H. et al.
Cancer Res.; published online May 7, 2013;
Contact: Alexander Levitzki, The Hebrew University of Jerusalem,
2. Pollak, M. Nat. Rev.
Cancer 12, 159-169 (2012)
AND INSTITUTIONS MENTIONED
Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif.
Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan
Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568), Tokyo, Japan
Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind.
The Hebrew University of Jerusalem, Jerusalem, Israel
McGill University, Montreal, Quebec, Canada
Meytav Technological Incubator, Kiryat-Shmona, Israel
NovoTyr Therapeutics Ltd., Kiryat-Shmona, Israel
Office of the Chief Scientist in the Ministry of Economy, Tel Aviv, Israel
Pfizer Inc. (NYSE:PFE), New York, N.Y.
(SIX:ROG; OTCQX:RHHBY), Basel, Switzerland
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel
University of Minnesota Masonic Cancer Center, Minneapolis, Minn.
University of Minnesota Medical School, Minneapolis, Minn.